Characteristics and management of cyclosporine-associated adverse gastrointestinal events
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Koh, Won Seon | - |
dc.contributor.author | Ko,Young Wook | - |
dc.contributor.author | Kim, Jeong Eun | - |
dc.contributor.author | Ko, Joo Yeon | - |
dc.contributor.author | Ro, Young Suck | - |
dc.date.accessioned | 2022-07-08T20:25:28Z | - |
dc.date.available | 2022-07-08T20:25:28Z | - |
dc.date.created | 2021-05-13 | - |
dc.date.issued | 2019-12 | - |
dc.identifier.issn | 0494-4739 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/146637 | - |
dc.description.abstract | Background: Cyclosporine (CS) is widely used to treat various skin diseases. Gastrointestinal (GI) discomfort is the most common adverse effect of orally administered CS for dermatologic indications. However, few studies on CS-associated adverse GI events have been conducted. Objective: In this study, we aimed to describe the major features of adverse GI events associated with CS therapy using a validated symptom questionnaire, and to investigate the factors contributing to their development. We also evaluated the effectiveness of three empirical GI medications in relieving adverse GI events. Methods: This study consisted of 2 phases. Phase I was a prospective observational cohort study to investigate the characteristics of CS-associated adverse GI events in 942 consecutive patients treated with CS. Phase II was a randomized controlled trial to evaluate the efficacy of three different classes of GI medications. Results: CS-associated adverse GI events occurred in 119 patients (12.6%). GI complications were more common in female patients (p=0.04), patients with a history of GI disorders (p=0.02), and patients whose initial CS doses were greater than 3 mg/kg/day (p=0.05). In patients treated with any one of the three GI medications, the mean Gastrointestinal Symptom Rating Scale scores significantly decreased (p<0.001). Conclusion: This study demonstrated that adverse GI events are common during early CS treatment, especially in women, patients receiving high doses of CS, and those with a history of GI disorders. Our results suggest that new-onset CS-associated GI side effects can be effectively managed with the addition of GI medications. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Korean Dermatological Association | - |
dc.title | Characteristics and management of cyclosporine-associated adverse gastrointestinal events | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Jeong Eun | - |
dc.contributor.affiliatedAuthor | Ko, Joo Yeon | - |
dc.contributor.affiliatedAuthor | Ro, Young Suck | - |
dc.identifier.scopusid | 2-s2.0-85079593198 | - |
dc.identifier.bibliographicCitation | Korean Journal of Dermatology, v.57, no.10, pp.608 - 616 | - |
dc.relation.isPartOf | Korean Journal of Dermatology | - |
dc.citation.title | Korean Journal of Dermatology | - |
dc.citation.volume | 57 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 608 | - |
dc.citation.endPage | 616 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002538193 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Cyclosporine | - |
dc.subject.keywordAuthor | Drug-related side effects and adverse reactions | - |
dc.subject.keywordAuthor | Gastrointestinal agents | - |
dc.subject.keywordAuthor | Risk factors | - |
dc.identifier.url | https://kiss.kstudy.com/thesis/thesis-view.asp?key=3735080 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.